title: [Quality of life and hypoglycemia burden in patients with type 2 diabetes mellitus on basal-bolus insulin therapy].
abstract: This paper presents the results of the observational program "Parameters of life quality, symptoms of hypoglycemia and treatment satisfaction in patients with type 2 diabetes mellitus on basal-bolus insulin therapy" (2012-2014). The analysis included 1000 patients. It showed that their quality of life was below that of the general population due to compromised physical, role physical, and role emotional functioning (p < 0.001). Hypoglycemia is a serious challenge to the treatment of patients with type 2 diabetes mellitus on basal-bolus insulin therapy. They are characterized by impaired physical, psychological, and social functioning compared with the patients without hypoglycemic episodes (p < 0.01). Patients experiencing mild hypoglycemic episodes were not significantly different from those without them. In patients experiencing severe hypoglycemic episodes the quality of life was much worse (ES = 0.22-0.51). The profile of hypoglycemic episodes differed in different forms of hypoglycemia. The spectrum of symptoms and problems related to hypoglycemia was broader in patients with severe and/or nocturnal hypoglycemia. Patients free from hypoglycemia were less afraid of it than those used to have hypoglycemic episodes (p < 0.001). The stronger the fear, the more pronounced disturbances in social functioning, vitality, psychic and general health (p = 0.0001). It is concluded that evaluation of quality of life and hypoglycemia-related symptoms in patients with type 2 diabetes mellitus on basal-bolus insulin therapy allows for comprehensive estimation of the effectiveness of therapy on an individual basis.
authors.forename: T I
authors.initials: TI
authors.lastname: Ionova
authors.forename: V I
authors.initials: VI
authors.lastname: Odin
authors.forename: T P
authors.initials: TP
authors.lastname: Nikitina
authors.forename: K A
authors.initials: KA
authors.lastname: Kurbatova
mesh_terms: D017281:Cost of Illness; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D005239:Fear / Q000502:physiology*; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control / Q000523:psychology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D009313:National Health Programs / Q000706:statistics & numerical data; D057240:Patient Preference; D011788:Quality of Life; D012426:Russia / Q000453:epidemiology; D012720:Severity of Illness Index; D064890:Social Determinants of Health; D013223:Statistics as Topic
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin